Catalyst Pharmaceutical Partners, Inc. to Announce Top-Line Data From CPP-109 Phase II(b) Clinical Trial for the Treatment of Cocaine Addiction Earlier Than Expected

CORAL GABLES, Fla., July 12, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that it expects to report top-line results from its CPP-109 (vigabatrin) Phase II(b) trial around the end of September 2012 versus the previous guidance of early in the first quarter of 2013.